Hualan Genetic to Develop Three Harbour BioMed Antibodies in Return for China Rights

Hualan Genetic Engineering agreed to develop three Harbour BioMed novel monoclonal and bispecific antibodies in return for China marketing rights to the candidates. Hualan Genetic, previously a company focused on biosimilars, will be responsible for preclinical and process development. It will also make an $8.75 million upfront payment, plus pay royalties. Harbour BioMed, which is headquartered in the US with R&D facilities in China , will retain the rights to the antibodies in the rest of the world. Both companies will collaborate on clinical developments and drug manufacturing. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.